At IBT Bioservices, we recognize the significance of addressing bacterial infections caused by enterotoxigenic Escherichia coli (ETEC), a major cause of diarrheal illness in both developed and developing countries. We provide preclinical testing services aimed at assessing the safety and efficacy of potential treatments and vaccines against E. coli ETEC.
Gastrointestinal infection, Urinary Tract Infections (UTIs), Bacteremia and Meningitis
Humans of all ages and backgrounds
Nausea, headaches, fever, abdominal pain, and in some cases life-threatening systemic inflammation.
E. coli is a gram-negative bacterium that causes severe foodborne illness or meningitis, posing a significant public health risk. Research and development are required to find effective treatments.
ETEC strains are known for producing enterotoxins that disrupt the normal functioning of the intestines, leading to severe diarrhea and dehydration. These infections pose a significant health burden, particularly in populations with limited access to clean water and proper sanitation. Developing effective interventions to combat E. coli ETEC is crucial in preventing illness, reducing morbidity, and saving lives.
At IBT, our expert team of scientists and researchers utilizes state-of-the-art facilities and advanced methodologies to perform thorough in vitro and animal testing models for E. coli ETEC.
ELISA
QPCR
Multiplex Assays
Using advanced molecular and cellular techniques, we evaluate the efficacy of potential drugs and vaccines against E. coli ETEC. These studies help identify compounds that can effectively inhibit bacterial growth, neutralize toxins, or modulate the host immune response.
Understanding how potential interventions are absorbed, distributed, metabolized, and eliminated by the body is crucial. Our comprehensive pharmacokinetic studies provide valuable insights into the intervention’s behavior, bioavailability, and optimal dosage. Additionally, toxicology evaluations ensure the safety of the treatment or vaccine candidates, assessing potential adverse effects and determining the appropriate dosage range.
We have developed a mouse model for ETEC colonization of gastrointestinal track that can be utilized to assess the safety and efficacy of potential interventions. Our experienced researchers closely monitor key parameters, including bacterial load, diarrhea severity, gut inflammation, immune response, and overall health, to evaluate the effectiveness of the tested treatments or vaccines. Our animal testing models provide critical data on the intervention’s ability to control bacterial growth, reduce disease severity, and enhance host immune responses.
At IBT Bioservices, we are committed to advancing the field of E. coli ETEC research and development through reliable and accurate in vitro and animal testing models. Our dedication to scientific excellence, ethical practices, and adherence to regulatory guidelines positions us as a trusted partner in the fight against this bacterial infection. We provide you with high quality data and documentation supporting your regulatory filings.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.